Tags

Type your tag names separated by a space and hit enter

Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis.
Ann Rheum Dis. 2008 Dec; 67(12):1736-8.AR

Abstract

OBJECTIVES

Early osteoporotic fractures have a great impact on disease progression, the first fracture being a major risk factor for further fractures. Strontium ranelate efficacy against vertebral fractures is presently assessed in a subset of women aged 50-65 years.

METHODS

The Spinal Osteoporosis Therapeutic Intervention (SOTI) was an international, double blind, placebo controlled trial, supporting the efficacy of strontium ranelate 2 g/day in reducing the risk of vertebral fractures in postmenopausal women with osteoporosis and a prevalent vertebral fracture. 353 of these randomly assigned women were included in this analysis.

RESULTS

Over 4 years, strontium ranelate significantly reduced the risk of vertebral fracture by 35% (relative risk 0.65; 95% CI 0.42 to 0.99, p<0.05). In the strontium ranelate group, the bone mineral density increased from baseline by 15.8% at lumbar spine and 7.1% at femoral neck.

CONCLUSION

These data demonstrate a significant vertebral antifracture efficacy of strontium ranelate in young postmenopausal women aged 50-65 years with severe osteoporosis and confirm the efficacy of this antiosteoporotic treatment to prevent vertebral fractures, whatever the age of the patient.

Authors+Show Affiliations

Département de Rhumatologie, AP-HP Hôpital Cochin, University Paris-Descartes, Paris 75014, France. christian.roux@cch.aphp.frNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

18713788

Citation

Roux, C, et al. "Strontium Ranelate Reduces the Risk of Vertebral Fracture in Young Postmenopausal Women With Severe Osteoporosis." Annals of the Rheumatic Diseases, vol. 67, no. 12, 2008, pp. 1736-8.
Roux C, Fechtenbaum J, Kolta S, et al. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis. 2008;67(12):1736-8.
Roux, C., Fechtenbaum, J., Kolta, S., Isaia, G., Andia, J. B., & Devogelaer, J. P. (2008). Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Annals of the Rheumatic Diseases, 67(12), 1736-8. https://doi.org/10.1136/ard.2008.094516
Roux C, et al. Strontium Ranelate Reduces the Risk of Vertebral Fracture in Young Postmenopausal Women With Severe Osteoporosis. Ann Rheum Dis. 2008;67(12):1736-8. PubMed PMID: 18713788.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. AU - Roux,C, AU - Fechtenbaum,J, AU - Kolta,S, AU - Isaia,G, AU - Andia,J B Cannata, AU - Devogelaer,J-P, Y1 - 2008/08/19/ PY - 2008/8/21/pubmed PY - 2008/12/17/medline PY - 2008/8/21/entrez SP - 1736 EP - 8 JF - Annals of the rheumatic diseases JO - Ann Rheum Dis VL - 67 IS - 12 N2 - OBJECTIVES: Early osteoporotic fractures have a great impact on disease progression, the first fracture being a major risk factor for further fractures. Strontium ranelate efficacy against vertebral fractures is presently assessed in a subset of women aged 50-65 years. METHODS: The Spinal Osteoporosis Therapeutic Intervention (SOTI) was an international, double blind, placebo controlled trial, supporting the efficacy of strontium ranelate 2 g/day in reducing the risk of vertebral fractures in postmenopausal women with osteoporosis and a prevalent vertebral fracture. 353 of these randomly assigned women were included in this analysis. RESULTS: Over 4 years, strontium ranelate significantly reduced the risk of vertebral fracture by 35% (relative risk 0.65; 95% CI 0.42 to 0.99, p<0.05). In the strontium ranelate group, the bone mineral density increased from baseline by 15.8% at lumbar spine and 7.1% at femoral neck. CONCLUSION: These data demonstrate a significant vertebral antifracture efficacy of strontium ranelate in young postmenopausal women aged 50-65 years with severe osteoporosis and confirm the efficacy of this antiosteoporotic treatment to prevent vertebral fractures, whatever the age of the patient. SN - 1468-2060 UR - https://www.unboundmedicine.com/medline/citation/18713788/Strontium_ranelate_reduces_the_risk_of_vertebral_fracture_in_young_postmenopausal_women_with_severe_osteoporosis_ L2 - https://ard.bmj.com/lookup/pmidlookup?view=long&amp;pmid=18713788 DB - PRIME DP - Unbound Medicine ER -